JMP Securities Reaffirms “Market Outperform” Rating for OptimizeRx (NASDAQ:OPRX)

OptimizeRx (NASDAQ:OPRX)‘s stock had its “market outperform” rating restated by stock analysts at JMP Securities in a research note issued on Thursday,Benzinga reports. They currently have a $8.00 target price on the stock. JMP Securities’ price target points to a potential upside of 44.93% from the company’s current price.

Several other brokerages have also issued reports on OPRX. Royal Bank of Canada reiterated a “sector perform” rating and issued a $6.00 target price (down previously from $7.00) on shares of OptimizeRx in a research report on Wednesday, January 8th. William Blair reaffirmed an “outperform” rating on shares of OptimizeRx in a research note on Thursday, November 14th. Lake Street Capital reiterated a “buy” rating and set a $11.00 price target on shares of OptimizeRx in a research report on Tuesday, December 24th. Stifel Nicolaus decreased their price objective on OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. Finally, Roth Mkm reaffirmed a “buy” rating and set a $16.00 target price (down previously from $20.00) on shares of OptimizeRx in a report on Thursday, November 14th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.06.

OptimizeRx Stock Performance

Shares of OPRX stock opened at $5.52 on Thursday. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. OptimizeRx has a 12-month low of $3.78 and a 12-month high of $16.65. The business’s 50 day moving average is $5.24 and its two-hundred day moving average is $6.55. The company has a market capitalization of $101.68 million, a P/E ratio of -4.15 and a beta of 1.38.

Insider Transactions at OptimizeRx

In other news, CEO William J. Febbo acquired 20,000 shares of OptimizeRx stock in a transaction dated Thursday, December 12th. The shares were acquired at an average cost of $5.01 per share, for a total transaction of $100,200.00. Following the acquisition, the chief executive officer now owns 601,253 shares of the company’s stock, valued at $3,012,277.53. This trade represents a 3.44 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. SBI Securities Co. Ltd. purchased a new position in OptimizeRx during the 4th quarter worth approximately $25,000. BNP Paribas Financial Markets grew its position in shares of OptimizeRx by 189.2% during the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after acquiring an additional 2,414 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of OptimizeRx in the 4th quarter valued at $51,000. Quest Partners LLC increased its holdings in shares of OptimizeRx by 15,965.6% in the 3rd quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock valued at $76,000 after acquiring an additional 9,739 shares during the period. Finally, Barclays PLC raised its position in OptimizeRx by 358.5% in the 3rd quarter. Barclays PLC now owns 26,934 shares of the company’s stock valued at $208,000 after purchasing an additional 21,060 shares during the last quarter. Institutional investors and hedge funds own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.